Katherine E. Fleming-Dutra

Pediatrics

1645 Tullie Cir NE
Atlanta, GA 30329

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.

Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.

Journal: Vaccine

Published: January 23, 2025

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.

Journal: Lancet regional health. Americas

Published: December 18, 2024

Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.

Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.

Journal: Vaccine

Published: December 11, 2024

Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.

Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.

Journal: Vaccine

Published: November 20, 2024

Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025.

Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025.

Journal: MMWR. Morbidity and mortality weekly report

Published: September 19, 2024

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Journal: MMWR. Morbidity and mortality weekly report

Published: August 15, 2024

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023.

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023.

Journal: Influenza and other respiratory viruses

Published: August 05, 2024

A framework for monitoring RSV prevention product effectiveness in the United States.

A framework for monitoring RSV prevention product effectiveness in the United States.

Journal: Vaccine

Published: July 15, 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.

Journal: Lancet (London, England)

Published: June 19, 2024

Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Journal: MMWR. Morbidity and mortality weekly report

Published: April 25, 2024

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.

Journal: MMWR. Morbidity and mortality weekly report

Published: March 28, 2024

Incorrect Administration of Adult RSV Vaccines to Young Children.

Incorrect Administration of Adult RSV Vaccines to Young Children.

Journal: Pediatrics

Published: March 25, 2024

Showing 1-12 of 126

Last Updated: 09/26/2026